Powers & Company announces formation of philanthropic program, Lion’s Share


The 2 organizations to receive initial gifts will be Sight for Life and Eye Corps.

Image credit: AdobeStock/amazing studio

(Image credit: AdobeStock/amazing studio)

Powers & Company has announced the formation of Lion’s Share, a philanthropic program, as well as the first 2 beneficial organizations.

Powers & Company is a healthcare marketing strategy and communications consultancy headquartered in Dana Point, CA, that partners with bioscience and healthcare clients at every stage of product lifecycle.

Lion’s Share will provide Powers & Company the ability to “provide strategic donations and volunteer support to organizations committed to fostering equitable access to healthcare,” according to the organization. The 2 organizations to receive initial gifts will be Sight for Life and Eye Corps.1

Sight for Life is a non-profit division of One World Global Health Network, dedicated to providing eye care and education to improve the lives of those in need worldwide. According to the press release, Sight for Life is a volunteer-led organization that is actively working on expanding its services to offer over 80 surgeries and 800 patient visits per mission.1

According to Powers & Company, Sight for Life was picked as one of their founding beneficiaries to “provide the delivery of eye care and to create lasting surgical and clinical solutions in the communities of St Vincent and the Grenadines through education, collaboration, and improved access to technology, training, equipment, and supplies.”1

“Sight for Life is thankful to receive support through the Lion’s Share initiative, as their commitment to our organization and donation has allowed us to bring crucial sight-preserving care to areas that lack modern medical services. Their support has been integral in helping us with our new eye hospital serving St. Vincent and the Grenadines, which will open later this year,” said ophthalmologist Cathleen McCabe, MD and Sight for Life Lead Volunteer for over 20 years.

The second organization, Eye Corps is a 501(c)(3) nonprofit foundation formed in 2017 with the mission to reduce blindness by providing vision screening and eye care to those in need. Furthermore, the organization aims to eliminate preventable blindness in sub-Saharan Africa through strategic partnerships with the local medical community and ophthalmic training institutions. The group has 4 sites in regional hospitals located in Kilimanjaro, Lindi, and Ruvuma regions of Tanzania, which will be the main recipients of the contribution.1

Carey Powers, founder and CEO of Powers & Company talked about the organizations receiving gifts in a press release.

“We’re grateful to both of these organizations for ensuring that patients with unmet needs have improved access to clinicians and medical services, and it’s an honor for us to support and volunteer with their life-changing work,” said Powers. “On day one, we established our company’s commitment to the principle of health equity, and it’s exciting for us to act on that value in our first year in business.”

Senior directors of marketing at Powers & Company, Hannah Austin and Tatum Hathaway, co-lead Lion’s Share by overseeing the company's philanthropic services.

  1. Powers & Company launches Lion’s Share, a philanthropic program advancing health equity. Press release; April 3, 2024. Accessed April 3, 2024. https://www.powers-co.com/post/powers-company-launches-lion-s-share-a-philanthropic-program-advancing-health-equity
Related Videos
Video 4 - "Treating Geographic Atrophy in Patients with Concurrent Neovascular AMD"
Video 3 - "Managing a Patient with Bilateral Geographic Atrophy"
Video 2 - "FDA-approved Therapies for Geographic Atrophy"
Video 1 - "Geographic Atrophy: Overview, Diagnosis, and Progression"
Marion Munk, MD, PhD, presenting slides
Marion Munk, MD, PhD, presenting slides
Retinal Inner Layer Disorganization and OCT in Uveitic Macular Edema: Insights from Dr. Amitha Domalpally
ARVO 2024: Study Reveals Faricimab's Potential for Extended Dosing in nAMD
© 2024 MJH Life Sciences

All rights reserved.